Phibro Animal Health Corporation
PAHCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Phibro Animal Health Corporation (PAHC) is listed under Drug Manufacturers - Specialty & Generic. The company carries a $1.55B market cap, placing it firmly in the small-cap category. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Market Cap
$1.55B
Beta
0.47
P/E (TTM)
15.74
P/E (Fwd)
9.93
EPS (TTM)
$2.43
EPS (Fwd)
$3.85
ROE
29.7%
ROA
8.5%
Cash
$84.0M
Total Debt
$795.6M
Free CF
-$19.3M
52W Change
-7.2%
Annual Financials
Cash vs Debt
Where PAHC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PAHC finished 5.47% below its 150-day moving average ($42.23) and 4.11% below its 200-day moving average ($41.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PAHC overbought or oversold?
At the September 3, 2026 close, PAHC's RSI(14) was 85.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Phibro Animal Health Corporation carries $795.6M in total debt against $84.0M in cash reserves — debt is roughly 9.5x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$19.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 29.7%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $942.3M (2022) to $1.52B (2026), reflecting a 61% increase over the period.
The relatively low beta of 0.47 suggests PAHC is a less volatile holding compared to the broader index. Phibro Animal Health Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PAHC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.